ChemoCentryx Inc. [NASDAQ: CCXI] slipped around -2.21 points on Thursday, while shares priced at $58.04 at the close of the session, down -3.67%. ChemoCentryx Inc. stock is now 46.75% up from its year-to-date (YTD) trading value. CCXI Stock saw the intraday high of $59.87 and lowest of $56.03 per share. The company’s 52-week high price is 64.31, which means current price is +88.93% above from all time high which was touched on 06/10/20.
Compared to the average trading volume of 651.15K shares, CCXI reached a trading volume of 2685690 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about ChemoCentryx Inc. [CCXI]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CCXI shares is $75.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CCXI stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for ChemoCentryx Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on May 27, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $60 to $69. The new note on the price target was released on May 12, 2020, representing the official price target for ChemoCentryx Inc. stock. Previously, the target price had yet another raise from $40 to $60, while H.C. Wainwright kept a Buy rating on CCXI stock. On November 26, 2019, analysts increased their price target for CCXI shares from 17 to 54.
The Average True Range (ATR) for ChemoCentryx Inc. is set at 3.62, with the Price to Sales ratio for CCXI stock in the period of the last 12 months amounting to 106.22. The Price to Book ratio for the last quarter was 59.22, with the Price to Cash per share for the same quarter was set at 2.97.
How has CCXI stock performed recently?
ChemoCentryx Inc. [CCXI] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.27. With this latest performance, CCXI shares gained by 2.69% in over the last four-week period, additionally plugging by 86.44% over the last 6 months – not to mention a rise of 567.89% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CCXI stock in for the last two-week period is set at 49.93, with the RSI for the last a single of trading hit 44.21, and the three-weeks RSI is set at 53.36 for ChemoCentryx Inc. [CCXI]. The present Moving Average for the last 50 days of trading for this stock 53.30, while it was recorded at 60.51 for the last single week of trading, and 32.96 for the last 200 days.
ChemoCentryx Inc. [CCXI]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and ChemoCentryx Inc. [CCXI] shares currently have an operating margin of -161.38. ChemoCentryx Inc.’s Net Margin is presently recorded at -153.59.
Return on Total Capital for CCXI is now -95.33, given the latest momentum, and Return on Invested Capital for the company is -91.86. Return on Equity for this stock declined to -137.40, with Return on Assets sitting at -28.28. When it comes to the capital structure of this company, ChemoCentryx Inc. [CCXI] has a Total Debt to Total Equity ratio set at 33.11. Additionally, CCXI Total Debt to Total Capital is recorded at 24.87, with Total Debt to Total Assets ending up at 10.45. Long-Term Debt to Equity for the company is recorded at 30.83, with the Long-Term Debt to Total Capital now at 23.16.
Reflecting on the efficiency of the workforce at the company, ChemoCentryx Inc. [CCXI] managed to generate an average of -$676,695 per employee. Receivables Turnover for the company is 32.34 with a Total Asset Turnover recorded at a value of 0.18.ChemoCentryx Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.20.
Earnings analysis for ChemoCentryx Inc. [CCXI]
With the latest financial reports released by the company, ChemoCentryx Inc. posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.22/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -18.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CCXI.
Insider trade positions for ChemoCentryx Inc. [CCXI]
There are presently around $2,617 million, or 70.80% of CCXI stock, in the hands of institutional investors. The top three institutional holders of CCXI stocks are: FMR LLC with ownership of 9,246,685, which is approximately 5.794% of the company’s market cap and around 4.70% of the total institutional ownership; RA CAPITAL MANAGEMENT, L.P., holding 4,176,910 shares of the stock with an approximate value of $251.66 million in CCXI stocks shares; and BLACKROCK INC., currently with $235.52 million in CCXI stock with ownership of nearly -4.964% of the company’s market capitalization.
Positions in ChemoCentryx Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 108 institutional holders increased their position in ChemoCentryx Inc. [NASDAQ:CCXI] by around 9,034,964 shares. Additionally, 57 investors decreased positions by around 5,328,053 shares, while 10 investors held positions by with 29,071,582 shares. The mentioned changes placed institutional holdings at 43,434,599 shares, according to the latest SEC report filing. CCXI stock had 50 new institutional investments in for a total of 3,237,177 shares, while 16 institutional investors sold positions of 2,177,910 shares during the same period.